

REMARKS

Claim Amendments

Upon entry of this amendment, Claims 194, 196, 198-206, 209-215, 217-256, and 310-317. Claims 194, 217, 218, and 253 are amended herein. Claims 310-317 are newly added. Support for these amendments can be found throughout the application as filed. For example, support for claims 310-317 can be found at paragraph [0075]. No new matter has been added.

Specification Amendments

Applicants have amended the specification to update the priority of Application Ser. No. 10/179,373 (“the ‘373 application”). Applicants have amended the claim for priority and submitted a petition to accept an unintentionally delayed claim of priority under 35 U.S.C. § 120 in the ‘373 application. No new matter has been added.

Statement of Substance of Interview Under 37 C.F.R. § 1.133(b)

In accordance with 37 C.F.R. § 1.133(b) and M.P.E.P. § 713.04, Applicants herein provide a summary of the interview. Applicants thank Examiner Landsman for agreeing to conduct the interview and appreciate the courtesies extended by the Examiner.

During the interview, the parties agreed to delete the term “sweet” from claim 164 as this is an inherent property of the heteromeric polypeptides of the invention. The parties also agreed to limit the claims, without prejudice or disclaimer, to human T1R polypeptides, polypeptides encoded by human T1R nucleic acid sequences, polypeptides encoded by nucleic acid sequences that hybridize to human T1R nucleic acid sequences under stringent hybridization conditions, and polypeptides possessing at least 90% sequence identity to human T1R polypeptides.

Applicants have amended the claims herein to reflect these changes.

Applicants also agreed to amend claim 253 to recite “neurotransmitter” and submit the references cited in co-pending Application No. 10/725,488 to support its argument that claim 253 is enabled.

Applicants have amended claim 253 to recite “neurotransmitter.” Further, Applicants submit that assays for testing compounds that modulate G protein-coupled receptors (of which the T1R family is a member) and T1R family mediated taste transduction such as neurotransmitter and hormone release are known in the art. *See e.g.*, paragraphs [0110] and

[0221]-[0232]; *see also* Sugita, et al. "Genetic Tracing Shows Segregation of Taste Neuronal Circuitries for Bitter and Sweet," *Science* 309(5735): 781-785, 2005 (abstract provided herein as **Exhibit A**); Ong et al., "Clinical Potential of GABAB Receptor Modulators," *CNS Drug Rev.*, 11(3): 317-34, 2005 (abstract provided herein as **Exhibit B**); Wang et al. "Activation of Family C G-Protein-Coupled Receptors by the Tripeptide Glutathione," *J. Biol. Chem.*, 281(13): 8864-70, 2006 (abstract provided herein as **Exhibit C**).

Finally, Applicants argued the provisional double-patenting rejection over co-pending Application Nos. 10/725,037, 10/725,103, and 10/725,472 is improper as these co-pending applications, like the instant application, are divisional applications of the '373 application and were filed as a result of the restriction requirement set forth in the '373 application. Nevertheless, Applicants agreed to submit a terminal disclaimer over U.S. Patent No. 6,955,887.

Applicants submit herewith a terminal disclaimer over U.S. Patent No. 6,955,887 and the fee required under 37 C.F.R. 1.20(d) for a small entity.

CONCLUSION

It is believed that these amendments and remarks should place this application in condition for allowance. A notice to that effect is respectfully solicited. If the Examiner has any questions relating to this response or the application in general he is respectfully requested to contact the undersigned so that prosecution of this application may be expedited.


It is believed that no fees are required for entry of this response, but should any fees be necessary, the Commissioner is authorized to charge such fees to the undersigned's **Deposit Account No. 50-0206**.

Respectfully submitted,

HUNTON & WILLIAMS, LLP

Dated: June 12, 2007

By:



Robin L. Teskin
Registration No. 35,030

Alexander H. Spiegler
Registration No. 56,625

HUNTON & WILLIAMS LLP
Intellectual Property Department
1900 K Street, N.W. Suite 1200
Washington, DC 20006-1109
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

RLT/AHS:ltm